Therapeutic and diagnostic methods for cancer

Patent metadata

Field	Value
Publication number	US-11300570-B2
Application number	US-201916371589-A
Country	US
Kind code	B2
Filing date	Apr 1, 2019
Priority date	Oct 6, 2016
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

First claim

What is claimed is:

1. A method of identifying and treating an individual having a cancer who may benefit from a treatment comprising a PD-L1 binding antagonist, the method comprising:
(a) determining that a tissue tumor mutational burden (tTMB) score from a tumor sample from the individual is at or above a reference tTMB score, thereby identifying the individual as one who may benefit from a treatment comprising a PD-L1 binding antagonist, wherein the reference tTMB score is 16 mutations per megabase, and wherein the PD-L1 binding antagonist is an anti-PD-L1 antibody comprising a heavy chain comprising hypervariable region (HVR)-H1 sequence of SEQ ID NO:19, HVR-H2 sequence of SEQ ID NO:20, and HVR-H3 sequence of SEQ ID NO:21; and a light chain comprising HVR-L1 sequence of SEQ ID NO:22, HVR-L2 sequence of SEQ ID NO:23, and HVR-L3 sequence of SEQ ID NO:24; and
(b) administering to the individual an effective amount of the PD-L1 binding antagonist based on the tTMB score from the tumor sample from the individual being at or above the reference tTMB score.

2. A method for selecting a therapy for, and treating, an individual having a cancer, the method comprising:
(a) determining that a tTMB score from a tumor sample from the individual is at or above a reference tTMB score, thereby identifying the individual as one who may benefit from a treatment comprising a PD-L1 binding antagonist, wherein the reference tTMB score is 16 mutations per megabase, and wherein the PD-L1 binding antagonist is an anti-PD-L1 antibody comprising a heavy chain comprising HVR-H1 sequence of SEQ ID NO:19, HVR-H2 sequence of SEQ ID NO:20, and HVR-H3 sequence of SEQ ID NO:21; and a light chain comprising HVR-L1 sequence of SEQ ID NO:22, HVR-L2 sequence of SEQ ID NO:23, and HVR-L3 sequence of SEQ ID NO:24;
(b) selecting a therapy comprising the PD-L1 binding antagonist for the individual based on the tTMB score from the tumor sample from the individual being at or above the reference tTMB score; and
(c) administering to the individual an effective amount of the PD-L1 binding antagonist.

3. A method of treating an individual having a cancer, the method comprising:
(a) determining a tTMB score from a tumor sample from the individual, wherein the tTMB score from the tumor sample is at or above a reference tTMB score, thereby identifying the individual as one who may benefit from treatment comprising a PD-L1 binding antagonist, wherein the reference tTMB score is 16 mutations per megabase, and
(b) administering an effective amount of a PD-L1 binding antagonist to the individual, wherein the PD-L1 binding antagonist is an anti-PD-L1 antibody comprising a heavy chain comprising HVR-H1 sequence of SEQ ID NO:19, HVR-H2 sequence of SEQ ID NO:20, and HVR-H3 sequence of SEQ ID NO:21; and a light chain comprising HVR-L1 sequence of SEQ ID NO:22, HVR-L2 sequence of SEQ ID NO:23, and HVR-L3 sequence of SEQ ID NO:24.

4. A method of treating an individual having a cancer, the method comprising administering to the individual an effective amount of a PD-L1 binding antagonist, wherein prior to the administering a tTMB score that is at or above a reference tTMB score has been determined from a tumor sample from the individual, thereby identifying the individual as one who may benefit from treatment comprising a PD-L1 binding antagonist, wherein the reference tTMB score is 16 mutations per megabase, and wherein the PD-L1 binding antagonist is an anti-PD-L1 antibody comprising a heavy chain comprising HVR-H1 sequence of SEQ ID NO:19, HVR-H2 sequence of SEQ ID NO:20, and HVR-H3 sequence of SEQ ID NO:21; and a light chain comprising HVR-L1 sequence of SEQ ID NO:22, HVR-L2 sequence of SEQ ID NO:23, and HVR-L3 sequence of SEQ ID NO:24.

5. The method of claim 4 , wherein the tTMB score reflects the level of somatic mutations in at least one gene set forth in a pre-determined set of genes relative to a reference level of somatic mutations in the pre-determined set of genes.

6. The method of claim 5 , wherein the pre-determined set of genes comprises about 300 to about 400 genes covering at least about 0.05 Mb to about 10 Mb.

7. The method of claim 5 ,
(i) wherein the somatic mutations are substitutions, deletions, and/or insertions; or
(ii) wherein the somatic mutations are protein-altering somatic mutations; or
(iii) wherein the substitutions, deletions, and/or insertions of (i) or (ii) are in coding regions; or
(iv) wherein the deletions and/or insertions of (i), (ii), or (iii) are indels.

8. The method of claim 4 ,
(i) wherein the tTMB score from the tumor sample is greater than, or equal to, about 16 mut/Mb; or
(ii) wherein the tTMB score from the tumor sample is greater than, or equal to, about 20 mut/Mb.

9. The method of claim 4 , wherein:
(i) the tTMB score or the reference tTMB score is represented as the number of somatic mutations counted per a defined number of sequenced bases; or
(ii) the defined number of sequenced bases of (i) is between about 100 kb to about 10 Mb; or
(iii) the defined number of sequenced bases of (ii) is about 1.1 Mb.

10. The method of claim 4 , wherein:
(i) the tTMB score or the reference tTMB score is an equivalent TMB value; or
(ii) the equivalent TMB value of (i) is determined by whole-exome sequencing (WES).

11. The method of claim 4 ,
(i) wherein the tumor sample has been determined to have a detectable expression level of PD-L1 in 1% or more of tumor cells in the tumor sample; or
(ii) wherein the tumor sample has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells that comprise 1% or more of the tumor sample; or
(iii) wherein the tumor sample has been determined to have an undetectable expression level of PD-L1 in the tumor cells in the tumor sample; or
(iv) wherein the tumor sample has been determined to have an undetectable expression level of PD-L1 in the tumor-infiltrating immune cells.

12. The method of claim 4 , wherein the anti-PD-L1 antibody is atezolizumab.

13. The method of claim 4 , further comprising administering to the individual an effective amount of a second therapeutic agent.

14. The method of claim 13 , wherein the second therapeutic agent is a cytotoxic agent, a growth-inhibitory agent, a radiation therapy agent, an anti-angiogenic agent, or a combination thereof.

15. The method of claim 4 , wherein the tumor sample is a formalin-fixed and paraffin-embedded (FFPE) tumor sample, an archival tumor sample, a fresh tumor sample, or a frozen tumor sample.

16. The method of claim 11 ,
(i) wherein the expression level of PD-L1 is a protein expression level; or
(ii) wherein the protein expression level of PD-L1 of (i) is determined using a method selected from the group consisting of immunohistochemistry immunofluorescence, flow cytometry, and Western blot; or
(iii) wherein the protein expression level of PD-L1 of (i) or (ii) is detected using an anti-PD-L1 antibody.

17. A method of treating an individual having a cancer, the method comprising administering to the individual an effective amount of atezolizumab monotherapy, wherein prior to the administering a tTMB score that is at or above a reference tTMB score of 16 mutations per megabase has been determined from a tumor sample from the individual, thereby identifying the individual as one who may benefit from treatment with atezolizumab monotherapy, wherein the tTMB score is represented as the number of somatic mutations counted per a defined number of sequenced bases of between about 100 kb to about 10 Mb.

18. The method of claim 4 , wh

Assignees

• Genentech Inc
• Found Medicine Inc

Inventors

• Fabrizio David
• Frampton Garrett M
• Hegde Priti
• Kowanetz Marcin
• Shames David
• Stephens Philip J
• Sun James Xin
• Yelensky Roman
• Zou Wei

Classifications

• G01N33/5759 Primary

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K38/1774

  Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules) · CPC title